|Mr. Scott Mitchell Greasley||CEO, MD & Exec. Director||1.15M||N/A||N/A|
|Mr. Matthew Dudek||Chief Financial & Governance Officer||282.67k||N/A||N/A|
|Mr. Dominic Burg||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Graham Robertson||Head of R&D||N/A||N/A||N/A|
|Mr. Lee Tamplin B.A.||Company Sec.||N/A||N/A||N/A|
Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
Anagenics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.